← Passage BIO, Inc. (PASG) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Passage BIO, Inc. (PASG)
Biological Products, (No Diagnostic Substances) · market cap $16M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Passage BIO (PASG) is a clinical-stage gene therapy company with a market cap of approximately $15M and a single disclosed pipeline asset, PBFT02, currently in Phase 2 development for Frontotemporal Dementia (FTD). The company carries net cash of $33.3M against a runway of roughly 7.7 months, creating acute financing pressure. With no disclosed revenue and cumulative losses exceeding $500M over the past five years, the near-term story is almost entirely a binary on PBFT02 data and the company's ability to stay solvent.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PBFT02 | Phase 2 | Frontotemporal Dementia |
Price & technical context
3-month
-21.4%
6-month
-15.2%
12-month
-47.9%
52-wk range
$3.32–$19.85
vs 50-day MA
-17.3%
vs 200-day MA
-42.9%
Realized vol
119.2%
Max drawdown
-85.3%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PASG (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.